Lipid-lowering therapy in low-risk patients.
Lipid-lowering therapy in low-risk patients.
复制标题
低风险患者的降脂治疗。
DOI：
--
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Thomas A. Pearson
中科院分区：
文献类型：
--
作者：
Thomas A. Pearson
AFCAPS/TexCAPS进入了一个充满了构思和实施的临床试验的领域，这些临床试验通常由行业资助，但由学术界的高技能团队独立进行。AFCAPS/TexCAPS也不例外。然而，从入选的目标人群而不是终点或使用的干预措施的角度对这些临床试验进行检查，开始显示出支持这些药物疗效的一致证据。斯堪的纳维亚辛伐他汀生存研究2检查了最高风险组，冠状动脉疾病的幸存者大多具有高度升高的低密度脂蛋白胆固醇（LDL-C）水平。胆固醇和复发事件研究3
AFCAPS/TexCAPS enters a field crowded by superbly conceived and implemented clinical trials, usually industryfunded but carried out independently by highly skilled teams from academia. AFCAPS/TexCAPS is no exception. However, examination of these clinical trials from the viewpoint of the target populations enrolled, rather than of the end points or interventions used, begins to show consistent evidence across a spectrum of risk in favor of the efficacy of these drugs. The Scandinavian Simvastatin Survival Study 2 examined the highest-risk group, survivors of coronary artery disease mostly with highly elevated low-density lipoprotein cholesterol (LDL-C) levels. The Cholesterol and Recurrent Events Study 3
影响因子：
37.8
作者：
FURBERG, CD;ADAMS, HP;YOUNG, B
通讯作者：
YOUNG, B